Hyperuricemia - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Hyperuricemia - Pipeline Review, H1 2016', provides an overview of the Hyperuricemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperuricemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hyperuricemia - The report reviews pipeline therapeutics for Hyperuricemia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hyperuricemia therapeutics and enlists all their major and minor projects - The report assesses Hyperuricemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hyperuricemia Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hyperuricemia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hyperuricemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Hyperuricemia Overview 8 Therapeutics Development 9 Pipeline Products for Hyperuricemia - Overview 9 Pipeline Products for Hyperuricemia - Comparative Analysis 10 Hyperuricemia - Therapeutics under Development by Companies 11 Hyperuricemia - Therapeutics under Investigation by Universities/Institutes 12 Hyperuricemia - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Hyperuricemia - Products under Development by Companies 16 Hyperuricemia - Products under Investigation by Universities/Institutes 17 Hyperuricemia - Companies Involved in Therapeutics Development 18 AstraZeneca Plc 18 CymaBay Therapeutics, Inc. 19 Jiangsu Hengrui Medicine Co., Ltd. 20 Kissei Pharmaceutical Co., Ltd. 21 Nippon Chemiphar Co., Ltd. 22 Polaris Pharmaceuticals, Inc. 23 Takeda Pharmaceutical Company Limited 24 Teijin Pharma Limited 25 Hyperuricemia - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Combination Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 (allopurinol + lesinurad) - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 arhalofenate - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 febuxostat - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 febuxostat XR - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 JPH-367 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 KGO-2142 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 KGO-2173 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 NC-2500 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 pegadricase - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 RDEA-3170 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecules to Inhibit Human Uric Acid Transporter 1 for Hyperuricemia - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 TMX-049 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 XEN-102 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Hyperuricemia - Recent Pipeline Updates 54 Hyperuricemia - Dormant Projects 58 Hyperuricemia - Discontinued Products 59 Hyperuricemia - Product Development Milestones 60 Featured News & Press Releases 60 Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11 60 Jun 30, 2015: New Indication for Teijin Pharma's Febuxostat in Europe 61 Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat 61 Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric 62 Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat 63 Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat 63 Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea 64 May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan 64 Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67 65 Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan 66 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 67 Disclaimer 68
List of Tables
Number of Products under Development for Hyperuricemia, H1 2016 9 Number of Products under Development for Hyperuricemia - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Hyperuricemia - Pipeline by AstraZeneca Plc, H1 2016 18 Hyperuricemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016 19 Hyperuricemia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 20 Hyperuricemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 21 Hyperuricemia - Pipeline by Nippon Chemiphar Co., Ltd., H1 2016 22 Hyperuricemia - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 23 Hyperuricemia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 24 Hyperuricemia - Pipeline by Teijin Pharma Limited, H1 2016 25 Assessment by Monotherapy Products, H1 2016 26 Assessment by Combination Products, H1 2016 27 Number of Products by Stage and Target, H1 2016 29 Number of Products by Stage and Mechanism of Action, H1 2016 31 Number of Products by Stage and Route of Administration, H1 2016 33 Number of Products by Stage and Molecule Type, H1 2016 35 Hyperuricemia Therapeutics - Recent Pipeline Updates, H1 2016 54 Hyperuricemia - Dormant Projects, H1 2016 58 Hyperuricemia - Discontinued Products, H1 2016 59
List of Figures
Number of Products under Development for Hyperuricemia, H1 2016 9 Number of Products under Development for Hyperuricemia - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Products, H1 2016 15 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Targets, H1 2016 28 Number of Products by Stage and Targets, H1 2016 28 Number of Products by Mechanism of Actions, H1 2016 30 Number of Products by Stage and Mechanism of Actions, H1 2016 30 Number of Products by Routes of Administration, H1 2016 32 Number of Products by Stage and Routes of Administration, H1 2016 32 Number of Products by Molecule Types, H1 2016 34 Number of Products by Stage and Molecule Types, H1 2016 34
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. EvolvRead More...
Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing apRead More...
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.